Somatic mutations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements, play a significant role in the pathogenesis of non-small-cell lung cancer (NSCLC), with treatment decisions often based upon the outcome of these genetic tests [1–5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.